The Food and Drug Administration (FDA) told the maker of Purell to discontinue marketing campaigns that includes claims for avoiding flu and ebola, according to an article on The New York Times website.
The campaigns also claim the product can prevent spread of MRSA and norovirus.
The FDA told Gojo Industries that its claims that Purell could reduce the potential for infection or prevent illnesses violated the Federal Food, Drug and Cosmetic Act.
The agency said it was reclassifying Purell as an unapproved drug, rather than an over-the-counter product.
Cleanliness in Hospitals: Clinical Priority and Community Perception
Dana-Farber Receives $50M Gift for Planned Cancer Hospital
Clarinda Regional Health Center Reports Data Security Incident
Gaps in Nurses' Environmental Cleaning Knowledge Grow Amid Rising EVS Pressures
Ground Broken on the Southern Nevada Forensic Facility